Vnitr Lek 2020, 66(3):169-179 | DOI: 10.36290/vnl.2020.046

Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment?

Jan Bultas
Ústav farmakologie 3. LF UK Praha

Proton pump inhibitors (PPIs) are popular and widely used "gastroprotectives". More than 10% of our population is treated. In addition to classical indications such as gastroduodenal peptic disease or gastroesophageal reflux disease, they are indicated for the reduction of hemorrhagic complications in the digestive tract during antithrombotic treatment. The effect of PPIs on reducing upper gastrointestinal bleeding in antithrombotic treatment (rivaroxaban, acetylsalicylic acid or a combination) was called into question by a recently published randomised mega-study - COMPASS pantoprazole. Treatment of PPIs is accompanied by a number of significant drug interactions, in particular a severe reduction in the bioactivation of clopidogrel and a reduction in the absorption of acetylsalicylic acid or dabigatran. As a result, the effect of these antithrombotics is reduced. A number of observational studies - in the indication of PPIs in the treatment of gastroduodenal or gastrooesophageal disease or when used in the treatment of PPIs in antithrombotic treatment - found a greater incidence of major vascular events and an increase in mortality. So are PPIs effective in protecting gastrointestinal bleeding and are they safe?

Keywords: antithrombotics, atherothrombotic diseases, proton pump inhibitors, H2 receptor blockers, clopidogrel, acetylsalicylic acid, overview.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bultas J. Are proton pump inhibitors an effective and safe drug not only in the prophylaxis of gastrointestinal bleeding in antithrombotic treatment? Vnitr Lek. 2020;66(3):169-179. doi: 10.36290/vnl.2020.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Moayyedi P, Eikelboom JW, Bosch J et al. Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and.or Aspirin in a Randomized, Double‑blind, Placebo‑controlled Trial, Gastroenterology 2019, DOI https:..doi.org.10.1053.j.gastro.2019. 04. 041
    2. Hussaarts GAM, Marijn Veerman GD, Jansman FGA et al, Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol 2019, 11: 1-34. Go to original source... Go to PubMed...
    3. Makunts T, Cohen IV, Awdishu L Analysis of postmarketing safety data for proton‑pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis, Scientific Reports 2019; 9: 2282. Go to original source... Go to PubMed...
    4. https: doi.org.10.1038.s41598-019-39335-7
    5. Wedemeyer RS, Blume H Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37: 201-211. Go to original source... Go to PubMed...
    6. Strand DS, Kim D, Peura DA 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017; 11(1): 27-37. Go to original source... Go to PubMed...
    7. Zvyaga T, Chang SY, Chen C et al. Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19. Drug Metabolism and Disposition 2012; 40: 1698-1711. Go to original source... Go to PubMed...
    8. Li L, Geraghty OC, Mehta Z et al, Age‑specific risks, severity, time course, and outcome of bleeding on long‑term antiplatelet treatment after vascular events: a population‑based cohort study. Lancet 2017; 390: 490-499. Go to original source... Go to PubMed...
    9. Kuwayama T, Osanai H, Ajioka M et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non‑valvular atrial fibrillation. J Arrhythm 2017; 33: 619-623. Go to original source... Go to PubMed...
    10. Stangier J, Stähle H, Rathgen K et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59. Go to original source... Go to PubMed...
    11. Bolek T, Samoš M, Stančiaková L et al. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther 2017; Apr 25. doi: 10.1097.MJT.0000000000000599https: ..www.ema.europa.eu.documents.product‑information.pradaxa‑epar‑product‑information_cs.pdf
    12. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    13. Bultas J Kyselina acetylsalicylová - stále neotřesitelné postavení i v roce 2018? Remedia 2018; 28: 127-136.
    14. Bultas J, Karetová D Enterosolventní forma kyseliny acetylsalicylové - ano, či ne? Remedia 2017; 27: 145-151.
    15. Charlot M, Grove EL, Hansen PR et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690. Go to original source... Go to PubMed...
    16. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917. Go to original source... Go to PubMed...
    17. Demcsak A, Lantos T, Balint ER et al. PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel - A Systematic Review and Meta‑Analysis. Front Physiol 2018; 9: 1550.Další literatura u autoraa na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
    18. Melloni C, Washam JB, Jones WS et al. Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: A Systematic Review. Circ Cardiovasc Qual Outcomes 2015; 8: 47-55. Go to original source... Go to PubMed...
    19. Khan SU, Lone AN, Asad ZUA et al., Meta‑analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease. Cardiovascular Revascularization Medicine, https:..doi.org.10.1016. j.carrev.2019. 02. 002
    20. Scally B, Emberson JR, Spata E et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta‑analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231-241. Go to original source... Go to PubMed...
    21. Ray WA, Chung CP, Murray KT et al, Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018; 320: 2221-2230. Go to original source... Go to PubMed...
    22. Zirk‑Sadowski J, Masoli JA, Delgado J et al. Proton‑Pump Inhibitors and Long‑Term Risk of CommunityAcquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66: 1332-1338. Go to original source... Go to PubMed...
    23. http:..www.sukl.cz.modules.medication.detail.php?code=0192580 & tab=prices
    24. Novotny M, Klimova B, Valis M PPI Long Term Use: Risk of Neurological Adverse Events? Front. Neurol 2019; 9: 1142. Go to original source... Go to PubMed...
    25. Kinoshita Y, Ishimura N, Ishihara S Advantages and Disadvantages of Long‑term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018; 24: 182-196. Go to original source... Go to PubMed...
    26. CCheung KS, Chan EW, Wong AYS et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28-35. Go to original source... Go to PubMed...
    27. Malfertheiner P, Kandulski A, Venerito M Proton‑pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 2017; 14) :697-710. Go to original source... Go to PubMed...
    28. Xie Z, Bowe B, Li T et al, Long‑term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International 2017; 91: 1482-1494. Go to original source... Go to PubMed...
    29. Zhou B, Huang Y, Li H et al. Proton‑pump inhibitors and risk of fractures: an update meta‑analysis. Osteoporos Int 2016; 27: 339-347. Go to original source... Go to PubMed...
    30. Juurlink DN, Dormuth CR, Huang A et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS ONE 2013; 8: e84890. Go to original source... Go to PubMed...
    31. Charlot M, Ahlehoff O, Norgard ML et al. Proton‑pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. Ann Int Med 2010; 153: 378-386. Go to original source... Go to PubMed...
    32. Shih CJ, Chen YT, Ou SM et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardio 2014; 177: 292-297. Go to original source... Go to PubMed...
    33. Pello Lazaro AM, Cristobal C, Franco‑Pelaez JA et al. Use of Proton‑Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. PLoS ONE 2017; 12: e0169826. Go to original source...
    34. Fortuna LA, Pawloski PA, Parker ED et al. Proton pump inhibitor use by aspirin‑treated coronary artery disease patients is not associated with increased risk of cardiovascular events. European Heart Journal - Cardiovascular Pharmacotherapy 2016; 2: 13-19. Go to original source... Go to PubMed...
    35. Shah NH, LePendu P, Bauer‑Mehren A et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE 2015; 10: e0124653. Go to original source... Go to PubMed...
    36. Landi SN, Sandler RS, Pate V et al. No increase in risk of acute myocardial infarction in privately insured adults prescribed proton pump inhibitors vs histamine-2 receptor antagonists (2002-2014). Gastroenterology 2018; 154: 861-873. Go to original source... Go to PubMed...
    37. Xie Y, Bowe B, Yan Y et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019; 365: 11580. Go to original source... Go to PubMed...
    38. Senmaru T, Fukui M, Tanaka M et al. Atrophic gastritis is associated with coronary artery disease. J Clin Biochem Nutr 2012; 51: 39-41. Go to original source... Go to PubMed...
    39. Lee M, Baek H, Park JS et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross‑sectional study. PLOS ONE 2018; 13: e0193646. Go to original source... Go to PubMed...
    40. Rang and Dales Pharmacology, 9. ed., Elsevier 2020

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.